SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
DANTZKER DAVID

(Last) (First) (Middle)
WHEATLEY PARTNERS, LP
747 THIRD AVENUE, SUITE 24A

(Street)
NEW YORK NY 10017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Neuro-Hitech, Inc. [ NHPI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/25/2007
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/25/2007 J 3,100 A (1) 445,386 I By Wheatley MedTech Partners, L.P.(2)
Common Stock 12/14/2007 P 100,000 A (3) 545,386 I By Wheatley MedTech Partners, L.P.(2)
Common Stock 12/14/2007 J 26,340 A (4) 571,726 I By Wheatley MedTech Partners, L.P.(2)
Common Stock 09/25/2007 J 4,680 A (1) 619,495 I By Wheatley New York Partners LP(2)
Common Stock 12/14/2007 P 150,000 A (3) 769,495 I By Wheatley New York Partners LP(2)
Common Stock 12/14/2007 J 17,560 A (4) 787,055 I By Wheatley New York Partners LP(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant to purchase Common Stock (5) 12/14/2007 P 50,000 12/14/2007 12/14/2012 Common Stock 50,000 (3) 50,000 I By Wheatley MedTech Partners, L.P.(2)
Warrant to purchase Common Stock (5) 12/14/2007 P 75,000 12/14/2007 12/14/2012 Common Stock 75,000 (3) 75,000 I By Wheatley New York Partners LP(2)
Option(6) $4.07 01/02/2008 A 4,687 06/30/2008 12/31/2017 Common Stock 4,687 $0 4,687 D
Option(7) $4.2 01/02/2008 A 18,750 07/02/2008(7) 01/02/2018 Common Stock 18,750 $0 18,750 D
Explanation of Responses:
1. The securities were acquired as liquidated damages from the issuer's failure to timely file a registration statement registering a portion of Wheatley MedTech Partners, L.P.'s and Wheatley New York Partners LP's shares.
2. The reporting person is a member of the general partner of the limited partnership that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuiniary interest therein.
3. These securities were purchased from the issuer on December 14, 2007 as part of a sale by the issuer of units for $4.00 per unit. Each unit consisted of one share of Common Stock and a warrant to acquire 0.5 share of Common Stock.
4. The securities were acquired pursuant to certain anti-dilution protections provided to Wheatley MedTech Partners, L.P. and Wheatley New York Partners LP in a prior private offering.
5. The exercise price of the warrants is $7.00 per share unless the warrants are exercised prior to the later of (i) April 30, 2008 or (ii) thirty days after a registration statement registering the shares of common stock underlying the warrants is declared effective by the Securities and Exchange Commission, in which case the exercise price will be $5.00 per share.
6. The option was issued pursuant to the issuer's Non-Management Directors Deferral Program and was granted under the issuer's 2006 Amended and Restated Incentive Stock Plan. The Non-Management Directors Deferral Program allows directors who are not employees of the issuer to elect to receive, quarterly, compensation for their service as members of the issuer's board, in part or in whole, in the form of options.
7. The option was issued pursuant to the issuer's Amended and Restated Non-Management Directors Deferral Program ("Program") and was granted under the issuer's 2006 Amended and Restated Incentive Stock Plan. The Program allows directors who are not employees of the issuer to elect to receive, annually, compensation for their service as members of the issuer's board, in part or in whole, in the form of options. The option shall vest as to 1,562 shares beginning on February 2, 2008 and each month thereafter until January 2, 2009.
/s/ David Barrett, attorney-in-fact 01/04/2008
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.